Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949
- Determine if cytogenetic abnormalities can predict clinical outcome, in terms of
response to treatment and survival, in patients with metastatic renal cell carcinoma
registered to the nephrectomy arm (arm I) of SWOG-8949.
- Correlate cytogenetic abnormalities and DNA content analysis (DNA index and S-phase
fraction) with clinical outcome.
OUTLINE: This is a partially prospective, partially retrospective, multicenter, companion
Paraffin-embedded tumor tissue specimens from patients enrolled in SWOG-8949 are evaluated
by cytogenetic analysis (e.g., presence of trisomy and loss of Y chromosome) and flow
cytometric analysis (e.g., presence of nondiploid cells and presence of abnormal
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Number of successes per number of evaluable samples
Robert P. Whitehead, MD
University of Texas
United States: Federal Government